Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Macrobid (nitrofurantoin) is an antibiotic prescribed mainly to treat and sometimes prevent uncomplicated urinary tract infections, including bladder infections caused by bacteria such as E. coli. It works by damaging bacterial DNA and cell walls in the urinary tract, but it is not effective for kidney infections, prostate infections, or infections outside the urinary system. Typical courses run five to seven days, and dosing, safety, and drug interactions differ for older adults, people with reduced kidney function, and those in late pregnancy. There are several important cautions and side effects to consider, so see below to understand more before assuming Macrobid is the right choice.
Because burning urination, urgency, pelvic pain, and fever can signal a simple bladder infection or something more serious like a kidney infection or an STI, guessing wrong can delay the care you need, and a free, instant, online symptom check can help you clarify what your symptoms may mean and decide whether to see a clinician today.
Last reviewed for medical accuracy: 09/24/2026
Macrobid (nitrofurantoin macrocrystals) is an antibiotic commonly prescribed to treat urinary tract infections (UTIs). It belongs to the nitrofuran class of antibiotics and works by killing bacteria responsible for infections in the bladder and urinary tract.
Macrobid is FDA-approved for:
Most people tolerate Macrobid well. Side effects may include:
If these effects persist or worsen, talk to your doctor.
Although rare, Macrobid can cause serious reactions. Contact a healthcare provider immediately if you experience:
For any symptoms that feel life-threatening or severe, seek emergency care or call 911.
Before starting Macrobid, discuss the following with your doctor:
Macrobid can interact with other medications and supplements. Common interactions include:
Always provide a full list of your current medications, including over-the-counter drugs and supplements, to your healthcare provider.
Your healthcare provider may:
If you have frequent UTIs, your doctor might suggest:
If your symptoms don’t improve within 2–3 days of starting Macrobid or if they worsen, contact your healthcare provider. Persistent fever, back pain, or chills can signal a more serious kidney infection (pyelonephritis) requiring prompt evaluation.
For a free, online symptom check, using the doctor approved Ubie Symptom Checker visit: https://ubiehealth.com/
Always speak to a doctor or qualified healthcare professional before starting or stopping any medication. If you’re unsure whether Macrobid is right for you, or if your condition is serious, don’t hesitate to reach out for medical advice.
(References)
* Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018 Jul;219(1):40-51. doi: 10.1016/j.ajog.2017.12.231. Epub 2018 Jan 2. PMID: 29305250.
* Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627. PMID: 29710295; PMCID: PMC6134435.
* Milazzo E, Orellana G, Briceño-Bierwirth A, Korrapati VK. Acute lung toxicity by nitrofurantoin. BMJ Case Rep. 2021 Apr 14;14(4). doi: 10.1136/bcr-2020-237571. Epub 2021 Apr 14. PMID: 33853812; PMCID: PMC8054053.
* Alghoraibi H, Asidan A, Aljawaied R, Almukhayzim R, Alsaydan A, Alamer E, Baharoon W, Masuadi E, Al Shukairi A, Layqah L, Baharoon S. Recurrent Urinary Tract Infection in Adult Patients, Risk Factors, and Efficacy of Low Dose Prophylactic Antibiotics Therapy. J Epidemiol Glob Health. 2023 Jun;13(2):200-211. doi: 10.1007/s44197-023-00105-4. Epub 2023 Jun 5. PMID: 37273158; PMCID: PMC10271986.
* Mahdizade Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E, Darbandi T, Ghanavati R, Darbandi A. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. Front Cell Infect Microbiol. 2023;13:1148603. doi: 10.3389/fcimb.2023.1148603. Epub 2023 Jul 27. PMID: 37577377; PMCID: PMC10414118.
* Frimodt-Møller N, Bjerrum L. Treating urinary tract infections in the era of antibiotic resistance. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(12):1301-1308. doi: 10.1080/14787210.2023.2279104. Epub 2023 Nov 24. PMID: 37922147.
* Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Powell M, Jarvis E, Dennison J, Sheets A, Butler D, Breton J, Janmohamed S. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024 Feb 24;403(10428):741-755. doi: 10.1016/S0140-6736(23)02196-7. Epub 2024 Feb 8. PMID: 38342126.
* Hadidi MF, Alhamami N, Alhakami M, Abdulhamid AS, Alsharif A, Alomari MS, Alghamdi YA, Alshehri S, Ghaddaf AA, Alsenani FM, Almadani H. Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis. World J Urol. 2024 Apr 8;42(1):221. doi: 10.1007/s00345-024-04922-5. Epub 2024 Apr 8. PMID: 38587648.
* Gkiourtzis N, Stoimeni A, Glava A, Chantavaridou S, Michou P, Cheirakis K, Lalayiannis AD, Hulton SA, Tramma D. Prophylaxis Options in Children With a History of Recurrent Urinary Tract Infections: A Systematic Review. Pediatrics. 2024 Dec 1;154(6). doi: 10.1542/peds.2024-066758. PMID: 39492618.
* Llor C, Monfà R, Garcia-Sangenís A, Leiva A, Marín-Cañada J, Sánchez-Calavera MA, Moragas A, Aguilar-Sánchez M, Troncoso-Mariño A, Rodríguez-Barrientos R, Molero JM, Ouchi D, Miranda-Jiménez C, Fernández-García S, Morros R. Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial. Lancet. 2026 Apr 25;407(10539):1603-1613. doi: 10.1016/S0140-6736(25)02171-3. Epub 2026 Apr 20. PMID: 42026010.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.